Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
11:38am, Tuesday, 10'th Aug 2021
Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.
What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"
10:04am, Monday, 09'th Aug 2021
Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q2 2021 Results - Earnings Call Transcript
09:20pm, Thursday, 29'th Jul 2021
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q2 2021 Results - Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates
07:00pm, Thursday, 29'th Jul 2021
Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
08:27am, Friday, 23'rd Jul 2021
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
What's Next For Bio-Rad Laboratories Stock After A 10% Rise In A Month?
07:30am, Tuesday, 20'th Jul 2021
The stock price of Bio-Rad Laboratories, a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% over the last y
Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021
04:15pm, Wednesday, 14'th Jul 2021
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the sec
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
12:01pm, Tuesday, 06'th Jul 2021
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products
05:00pm, Wednesday, 30'th Jun 2021
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegen
Why 4 Jefferies Franchise List Stocks Could Be Big Second-Half Winners
07:45am, Monday, 14'th Jun 2021
It is hard to believe, but in just over two weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.
Why I Relish Low-Debt Stocks
10:11am, Monday, 10'th May 2021
When it comes to picking stocks, most investors go gaga over earnings and pay little attention to a company's financial strength.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
10:31am, Friday, 30'th Apr 2021
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2021 Results - Earnings Call Transcript
12:29am, Friday, 30'th Apr 2021
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2021 Results - Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
06:47pm, Thursday, 29'th Apr 2021
Bio-Rad (BIO) delivered earnings and revenue surprises of 108.40% and 9.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioRad (BIO) to Report Q1 Earnings: What's in the Cards?
09:01am, Monday, 26'th Apr 2021
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
